# MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma

> **NCT04555551** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 17 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **BIOLOGICAL:** Infusion of MCARH109 T cells

## Key facts

- **NCT ID:** NCT04555551
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-09-08
- **Primary completion:** 2026-08
- **Final completion:** 2026-08
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2025-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04555551

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04555551, "MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04555551. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*